**Summary**
N4 Pharma plc, a UK biotech company developing the Nuvec® gene delivery system for advanced therapies, has announced a partnership with the University of Strathclydes CMAC (Centre for Continuous Manufacturing and Crystallisation) National Facility. This collaboration aims to accelerate the development of Nuvec® and expand its therapeutic applications by combining N4 Pharmas innovative delivery platform with CMACs world-class expertise in drug delivery, RNA vaccines, and nanomedicine manufacturing.
Key highlights
The partnership will focus on advancing Nuvec® towards clinical readiness and characterizing dual-loaded Nuvec® preclinical candidates.
Professor Yvonne Perrie, MBE, a renowned expert in drug delivery and RNA vaccines, will lead the collaboration alongside CMACs National Facility team and N4 Pharmas scientists.
The collaboration leverages CMACs unique configuration of academic research, applied projects, and pre-competitive programs to transform medicine development and manufacturing.
N4 Pharma aims to position Nuvec® as a leading gene delivery platform for nucleic acid therapies, supporting its internal pipeline and future licensing opportunities.
The partnership highlights the strength of industry-academic collaborations in accelerating medicines manufacturing and unlocking new possibilities in RNA therapeutics.
This collaboration is expected to strengthen N4 Pharmas commercial data package for Nuvec® and bring the platform closer to clinical application, ultimately benefiting patients with cancer and other diseases.